John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.

Articles by John Carroll

Merck KGaA gets green light on lung cancer vax program

Merck KGaA got the green light from the FDA to restart its late-stage lung cancer program for its therapeutic vaccine Stimuvax, which had been halted after a patient in a multiple myeloma trial

Merck faces new delay at FDA as Gardasil sales slip

Merck is going to have to wait a little longer to see if its campaign to extend an approval for the cervical-cancer vaccine Gardasil to older women has succeeded with regulators. The pharma giant

FDA readies new vax safety site

The FDA has posted a new Web site that spells out the safety information that has been gleaned from recently launched vaccines and biologics. The agency is using the site to share what safety

Swine flu vaccine guards against lethal 1918 virus

Last year's H1N1 flu vaccine proved a safeguard against the deadly 1918 Spanish flu, which has managed to raise fresh fears of its bioterror potential since researchers were able to painstakingly

NanoBio scouting for fresh talent to expand vax research ops

Ann Arbor, MI-based NanoBio is beefing up its vaccine work after gaining a significant tax credit from the state. The University of Michigan spinoff is planning to hire 32 workers, with most of the

Gates, UN outline multibillion-dollar plan for women and children

The UN is rolling out an action plan aimed at saving the lives of 10 million women and children over the next five years, and vaccines are a central theme of the effort. The plan has the backing of

Vaccine myths fuel some stubborn consumer fears

One of the biggest problems vaccine manufacturers face is a widespread fear of their products. And even though much of that fear is completely baseless, it's hard to fight. GlaxoSmithKline produced

Experimental vax targets a key atherosclerosis trigger

Researchers at the prestigious Karolinska Institute in Sweden are working on a new vaccine that could prevent the body from dispatching T cells to help ward off "bad" LDL cholesterol, inadvertently

Pfizer forced to sell Chinese rights to a vaccine

In order to clear its way with Chinese regulators, Pfizer has been forced to sell one of its pig vaccines to a Chinese company for about $50 million. And observers say that the move signifies a

Brain cancer vax promising in PhI

A small Phase I trial of an experimental dendritic cell-based brain cancer vaccine advanced by ImmunoCellular Therapeutics (IMUC) has produced some unusually positive results. Only 16 patients